Table 1A.

Demographic and clinical characteristics by group

Characteristic	Non-remitters			Remitters			All MDD			Healthy controls
	Mean	SD	n	Mean	SD	n	Mean	SD	n	Mean	SD	n
Age of first visit	34.98	13.69	38	28.34	7.10	37	31.70	11.38	75	29.93	10.91	31
Years of education	14.00	3.14	38	14.65	2.41	37	14.32	2.80	75	14.84	2.72	31
Duration of illness	14.61	13.26	38	8.32	6.48	37	11.50	10.88	75	—	—	—
Number of prior episodes	19.95	11.93	38	19.54	7.70	37	19.75	10.00	75	—	—	—
Body mass index	25.31	4.91	32	26.16	6.29	35	25.75	5.65	67	—	—	—
Attention	−0.04	0.86	33	0.03	0.43	35	0.00	0.67	68	0.09	0.46	30
Cognitive flexibility	0.36	1.27	33	−0.01	0.73	35	0.17	1.04	68	0.05	0.50	30
Decision speed	−0.17	1.69	33	−0.02	0.57	35	−0.09	1.24	68	−0.08	0.77	30
Executive functioning	0.20	0.97	33	−0.19	1.4	35	0.00	1.22	68	0.15	0.47	26
Information processing speed	0.17	0.77	33	0.08	0.54	34	0.12	0.66	67	0.11	0.53	30
Motor coordination	−0.12	0.36	33	−0.12	0.45	35	−0.12	0.41	68	−0.06	0.58	30
Response inhibition	−0.07	0.72	32	−0.01	0.43	35	−0.04	0.58	67	0.07	0.53	29
Verbal memory	−0.15	0.73	33	0.09	0.9	35	−0.03	0.83	68	0.02	0.82	30
Working memory	−0.24	1.09	33	−0.03	1.07	35	−0.14	1.08	68	0.23	1.12	30
Number of early-life stressors	4.34	2.09	35	3.22	2.69	37	3.76	2.46	72	0.88	1.28	26
HRSD17 total Sscore at baseline	20.5	3.32	38	21.78	4.34	37	21.13	3.88	75	1.10	1.30	30
HRSD17 anxiety score at baseline	6.87	2.06	38	6.97	1.89	37	6.92	1.96	75	0.45	0.63	29
QIDS-SR16 total score at baseline	13.67	3.39	36	14.08	4.02	37	13.88	3.70	73	2.23	1.77	26
Dosage
Escitalopram	15.00	11.68	12	10.00	4.26	12	12.50	8.97	24	—	—	—
Sertraline	62.50	25.48	14	55.77	29.14	13	59.26	26.99	27	—	—	—
Venlafaxine	100.00	36.93	12	81.25	21.65	12	90.62	31.11	24	—	—	—
Equivalent dosagea
Escitalopram	112.50	87.58	12	75.00	31.98	12	93.75	67.26	24	—	—	—
Sertraline	93.75	38.21	14	83.65	43.72	13	88.89	40.48	27	—	—	—
Venlafaxine	100.00	36.93	12	81.25	21.65	12	90.62	31.11	24	—	—	—

^aEquivalent dosage in venlafaxine (7.5 × escitalopram; 1.5×sertraline; 1×venlafaxine)